Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

AnGes buys into Vical vaccine

June 5, 2006 | A version of this story appeared in Volume 84, Issue 23

Tokyo-based AnGes MG will pay up to $100 million for access to Allovectin-7, a cancer immunotherapy being developed by the San Diego-based biopharmaceutical company Vical. AnGes will initially pay $22.6 million, which includes a $6.9 million equity stake in Vical, for rights to market Allovectin-7 in certain Asian countries. Vical retains rights to market the drug in the U.S. The cash influx will fund a Phase III pivotal trial of Allovectin-7 to treat patients with metastatic melanoma. Allovectin-7, a plasma-lipid complex containing the DNA sequences that encode the MHC-1 antigen, is injected directly into tumor lesions to evoke an immune response.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.